Skip to content
MDFM News: PROSTATE CANCER at ASCO GU: 18 months of androgen blockade as safe and effective as 36 months in node-negative high-risk patients

MDFM News: PROSTATE CANCER at ASCO GU: 18 months of androgen blockade as safe and effective as 36 months in node-negative high-risk patients

Get the podcast

Other headlines: – Raised incidence of HPV-associated cancers in the past 35 years in the United States. – Two new anticoagulants for the extended treatment of patients with unprovoked ven

The Audio Journal of Oncology

Other headlines:
– Raised incidence of HPV-associated cancers in the past 35 years in the United States.

– Two new anticoagulants for the extended treatment of patients with unprovoked venous thromboembolism.

– Opioid analgesics drove increase in drug overdose deaths in 2010.

– Respiratory symptoms vary throughout menstrual cycle.

– Smoking bans in Belgium associated with reductions in risks of preterm delivery.

– Hydroxyethyl starch associated with a greater risk of death and acute kidney injury in critically ill patients requiring volume resuscitation.

Next in ASCO

All 85 interviews

Interview 50 of 85

ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings

ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings

CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical s

11 June 2012

Related Episodes

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA

15 Oct 2026
6 min
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.

8 Sep 2026
9 min
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.

31 Aug 2026
13 min